|
|
|
|
|
|
|
|
|
|
|
|
|
05.08.26 - 22:48
|
Novanta Announces Financial Results for the Second Quarter 2026 (Business Wire)
|
|
|
Second Quarter 2026 GAAP Revenue increased 10% to $266 million
Second Quarter 2026 GAAP Net Income was $13 million, and Adjusted EBITDA increased 16% to $61 million
Second Quarter 2026 GAAP Diluted EPS was $0.30, and Adjusted Diluted EPS increased 17% to $0.89
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2026.
Financial Highlights
Three Months Ended
(In millions, except per share amounts)
July 3,
June 27,
2026
2025
GAAP
Revenue
$
265.8
$
241.0
Operating Income
$
18.1
$
14.9
Net Income
$
12.5
$
4.5
Diluted EPS
$
0.30
$
0.12
Non-GAAP*
Adjusted Operating Income
$
47.5
$
40.7
Adjusted Diluted EPS
$
0.89
$
0.76
Adjusted EBITDA
$
60.7
$
52.2
*Reconciliations of GAAP to non-GAAP financial measures, as well as ...
|
|
|
|
|
27.07.26 - 14:06
|
Novanta Completes Acquisition of Riverpoint Medical (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today announced that it has completed the acquisition of Riverpoint Medical (“Riverpoint Medical” or “Riverpoint”) from Arlington Capital Partners. Riverpoint is a category leader in high-growth minimally invasive surgical consumables, including advanced surgical fibers and related technologies for sports medicine, trauma and cardiovascular surgical applications.
“Riverpoint Medical is a market-leading, high-growth surgical consumables business growing revenue and cash flow at twice Novanta's rate, and the acquisition is expected to double Novanta's recurring medical consumables revenue to roughly $300 million while pushing medical end-market exposure to 60% of total revenue,” said Matthijs Glastra, Novanta's Chair & Chief Executive Officer. “Beyond the top-line boost, we believe the deal unlocks a $2 billion in...
|
|
|
15.07.26 - 16:31
|
Novanta Aktie: Mit Übernahme das Wachstum weiter ankurbeln (Aktiencheck)
|
|
|
Paris (www.aktiencheck.de) - Novanta-Aktienanalyse von BNP Paribas:
Egmond Haidt von BNP Paribas nimmt die Aktie des US-Anbieters von Präzisionskomponenten für Medizintechnik- und Industrieunternehmen Novanta Inc. (ISIN: CA67000B1040, WKN: A2AJW7, Ticker-Symbol: 1GSN, NASDAQ-Symbol: NOVT) unter die Lupe. [mehr]...
|
|
|
14.07.26 - 23:03
|
Novanta Inc. Announces Schedule of Second Quarter 2026 Earnings Release and Conference Call (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2026 results after the close of U.S. financial markets on Wednesday, August 5, 2026.
The Company will host a conference call on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com.
A replay of the audio webcast will be available approximately three hours after the conclusion of the call on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. The replay will remain available until Monday, October 5, 2026.
About Novanta
Novanta is a leading global supplier of core technology solutions...
|
|
|
|
|
|
|
|
|
|
|
|
|
09.06.26 - 12:18
|
Novanta Inc. Announces $300 Million Private Placement (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--Novanta Inc. ("Novanta" or the “Company”) announced today that it has entered into a securities purchase agreement for a private placement of the Company's common shares (“Common Shares”) to institutional and other accredited investors that is expected to result in gross proceeds of approximately $300 million to the Company, before placement agent fees and offering expenses.
Pursuant to the terms of the securities purchase agreement, the investors agreed to purchase an aggregate of 2,142,857 Common Shares at a purchase price of $140.00 per share. The private placement is expected to close on or about June 11, 2026, subject to satisfaction of customary closing conditions.
The offer and sale of the foregoing Common Shares are being made in a transaction not involving a public offering and the Common Shares have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States except pursuant to an effective r...
|
|
|
09.06.26 - 12:06
|
Novanta Inc. Announces Acquisition of Riverpoint Medical (Business Wire)
|
|
|
Accelerates Novanta's strategic direction, expands portfolio into high-growth minimally invasive surgery segment, and doubles recurring medical consumables revenue
Transaction is immediately accretive to Novanta's revenue growth, Adjusted Gross and EBITDA margins, Adjusted Diluted EPS, and Operating Cash Flows
BOSTON--(BUSINESS WIRE)--Novanta Inc. (NASDAQ: NOVT) (“Novanta” or the “Company”), a trusted technology partner to leading global medical and industrial original equipment manufacturers (OEMs), today announced that it has entered into a definitive agreement to acquire Riverpoint Medical (“Riverpoint Medical” or “Riverpoint”), a category leader in high-growth minimally invasive surgical consumables, from Arlington Capital Partners (“Arlington”), a Washington D.C.-area private investment firm. Under the terms of the agreement, Novanta will acquire all outstanding equity interests of the parent company of Riverpoint Medical for an upfront cash consideration of $1.2 billion and a m...
|
|
|
|
|
20.05.26 - 17:31
|
Here′s Why Novanta (NOVT) Looks Ripe for Bottom Fishing (Zacks)
|
|
|
Novanta (NOVT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
